Ann: Change of Director's Interest Notices x2, page-79

Notable highlights in 2021 include: Published compelling preclinical data from Yale University in The Journal of Clinical Investigation—Insight confirming the ability of PAT-DX1 to cross the blood-brain barrier, and supporting its potential to be used for primary and secondary brain cancers. Announced a successful preclinical study from the Garvan Institute showing that PAT-DX1 is able to slow tumour growth and increase survival in an animal model of pancreatic cancer. Released new data demonstrating that PAT-DX3 can be used as a targeting agent for antibody drug conjugates (ADC) to deliver anti-cancer drugs to tumours in an animal model. Established a collaboration with Imagion Biosystems to develop new, improved imaging agents for brain cancers using Patrys’ deoxymabs. Expanded Patrys’ intellectual property portfolio with the granting of a US patent for our deoxymab assets. A successful $7.8 million capital raise to support further research and development activities.